An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Lucey, Brendan P ^a   Gonzales, Celedon ^b   Das, Ujjwas ^c   Li, Jinhe ^c   Siemers, Eric R ^b   Slemmon, J Randall ^d   Bateman, Randall J ^a   Huang, Yafei ^e   Fox, Gerard B ^c   Claassen, Jurgen A H R ^f   Slats, Diane ^f   Verbeek, Marcel M ^g   Tong, Gary ^h   Soares, Holly ⁱ   Savage, Mary J ^j   Kennedy, Matthew ^j   Forman, Mark ^j   Sjögren, Magnus ^k   Margolin, Richard ^l   Chen, Xia ^m   Farlow, Martin R ⁿ   Dean, Robert A ^b   Waring, Jeffrey F ^c   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c ABBVIE INC   (United States)

^d JOHNSON AND JOHNSON   (United States)

^e ST LUKE S HOSPITAL   (United States)

^f RADBOUD UNIVERSITY   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h LUNDBECK RESEARCH USA   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k Mental Health Centre Ballerup   (Denmark)

^l CereSpir Inc   (United States)

^m Boeringher Ingelheim   (United States)

ⁿ INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ARTICLE; CIRCADIAN RHYTHM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INDWELLING CATHETER; INDWELLING LUMBAR CATHETER; INTERMETHOD COMPARISON; LUMBAR PUNCTURE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADULT; AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COMPARATIVE STUDY; DEVICES; FEMALE; MALE; MIDDLE AGED; PHOTOPERIODICITY; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL; TIME FACTOR; YOUNG ADULT;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; CATHETERS, INDWELLING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PHOTOPERIOD; REPRODUCIBILITY OF RESULTS; SPINAL PUNCTURE; TIME FACTORS; YOUNG ADULT;

EID: 84938313416     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0136-z     Document Type: Article

References (36)

1. James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. Neurology. 2014;82:1-6.
2. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368:1326-34.
3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280-92.
4. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367:795-804.
5. Fagan AM, Mintun MA, Mach RH, Lee S-Y, Dence CS, Shah AR, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid amyloid-beta-42 in humans. Ann Neurol. 2006;59:512-9.
6. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-6.
7. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119-28.
8. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-β levels: implications for a diagnostic and therapeutic biomarker. Neurology. 2007;68:666-9.
9. Moghekar A, Goh J, Li M, Albert M, O'Brien RJ. Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. Arch Neurol. 2012;69:246-50.
10. Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, Ju Y-E, et al. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch Neurol. 2012;69:51-8.
11. Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, Morris JC, et al. Beta-amyloid dynamics in human plasma. Arch Neurol. 2012;69:1591-7.
12. Li J, Llano DA, Ellis T, LeBlond D, Bhathena A, Jhee SS, et al. Effect of human cerebrospinal fluid sampling frequency on amyloid-β levels. Alzheimers Dement. 2012;8:295-303.
13. Cho J-E, Kim JR. Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease. Recent Pat CNS Drug Discov. 2011;6:222-33.
14. Siemers E, Skinner M, Dean RA, Gonzales C, Satterwhite J, Farlow M, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005;28:126-32.
15. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer's disease. Arch Neurol. 2008;65:1031-8.
16. Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69:1002-10.
17. Farlow M, Arnold SE, Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement. 2012;8:261-71.
18. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, et al. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. 2009;66:48-54.
19. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, et al. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:6-15.
20. Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, et al. Measurement of Ab1-42 in cerebrospinal fluid is influenced by matrix effects. J Neurochem. 2012;120:325-33.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44.
22. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975;12:189-98.
23. Hachinski VC, Iliff LD, Zilhka E, Boulay GHD, McAllister VL, Marshall J, et al. Cerebral blood flow in dementia. Arch Neurol. 1975;32:632-7.
24. Farlow MR, Li H-I, Skinner M, May P, Hyslop PA, Bender MH, et al. Basal Aβ levels in plasma and cerebrospinal fluid of healthy subjects and patients with Alzheimer disease. Neurology. 2002;S59:001.
25. Siemers E, Quinn J, Kaye J, Farlow M, Porsteinsson A, Tariot P, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology. 2006;66:602-4.
26. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol. 2007;30:317-25.
27. Farlow MR, Dean RA, Satterwhite J, May PC, Siemers ER. Determination of Aβ concentrations in serial samples of human cerebrospinal fluid. In: Alzheimer"s Association 9th International Conference on Alzheimer's Disease and Related Disorders; 2004 July 17-22; Philadelphia, PA.
28. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12:856-61.
29. Bateman RJ, Munsell LY, Chen X, Holtzman DM, Yarasheski KE. Stable isotope labeling tandem mass sepctrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrom. 2007;18:997-1006.
30. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, et al. Robust central reduction of amyloid-beta in humans with an orally available, non-peptidic beta-secretase inhibitor. J Neurosci. 2011;31:16507-16.
31. Slats D, Claassen JA, Spies PE, Borm G, Besse KT, Aalst WV, et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol Aging. 2012;33:831. e1-9.
32. Tononi G, Cirelli C. Sleep function and synaptic homeostasis. Sleep Med Rev. 2006;10:49-62.
33. Lucey BP, Bateman RJ. Amyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis. Neurobiol Aging. 2014;35:S29-34.
34. Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol. 2014;71:971-7.
35. Tarnaris A, Toma AK, Chapman MD, Petzold A, Keir G, Kitchen ND, et al. Rostrocaudal dynamics of CSF biomarkers. Neurochem Res. 2011;36:528-32.
36. Mawuenyega KGSW, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, et al. Decreased clearance of CNS β-Amyloid in Alzheimer's disease. Science. 2010;330:1774.